FIELD: experimental therapy. SUBSTANCE: uridine in dose 50 mg per 1 kg body weight daily is administered for 6 to 8 days. EFFECT: affected all pathogenetic phases of disease. 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREVENTING AND TREATING ATHEROSCLEROSIS | 1998 |
|
RU2148399C1 |
MEANS FOR TREATING INSULIN RESISTANCE | 1999 |
|
RU2158590C1 |
METHOD FOR PERFORMING RIGHT SIDE PULMONECTOMY WITH TRACHEAL BIFURCATION EXSECTION IN LUNG CANCER PATIENTS | 1995 |
|
RU2065291C1 |
SURGICAL METHOD FOR TREATING POSTTRAUMATIC SUBCAPSULAR SPLEEN HEMATOMA | 1996 |
|
RU2099097C1 |
METHOD FOR TREATING PATIENTS SUFFERING FROM CHRONIC ARTERIAL INSUFFICIENCY OF LOWER EXTREMITIES | 2000 |
|
RU2162356C1 |
AGENT FOR TREATMENT OF PATIENTS WITH HYPERLIPIDEMIA AND ATHEROSCLEROSIS | 1999 |
|
RU2164408C2 |
METHOD FOR DIAGNOSIS OF AUTOIMMUNE DISEASES OF THYROID GLAND | 1996 |
|
RU2104531C1 |
ANTIBACTERIAL AGENT | 1999 |
|
RU2157686C1 |
METHOD FOR PREDICTING PULMONARY ASPHYXIA HEMORRHAGES | 2000 |
|
RU2156109C1 |
METHOD OF TREATMENT OF PATIENTS WITH DIABETES MELLITUS | 1996 |
|
RU2134109C1 |
Authors
Dates
1999-03-10—Published
1995-12-08—Filed